Ford C., Goodman AD, Johnson K., et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler2010 ; 16: 342-350.
2.
Fisher E., Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology2002; 59: 1412-1420.
3.
Bermel RA, Weinstock-Guttman B., Bourdette D., Foulds P., You X. and Rudick RAIntramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler , OnlineFirst DOI: 10.1177/i352458509360549.
4.
Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology2006 ; 67: 944-953.
5.
Reder T., Ebers GC, Traboulsee A., et al. Cross-Sectional Study assessing long-term safety of interferon-Beta-1b for relapsing-remitting MS. Neurology2010 ; 74; 1877- 1885.
6.
Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology1998; 50: 701-708.
7.
Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing remitting multiple sclerosis patients observed for 6 years. Mult Scler2000; 6: 255-266.
8.
Johnson KP, Ford CC, Lisak RP and Wolinsky JSGlatiramer acetate (Copaxone): neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand2005; 111: 42-47.
9.
Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifroni G. and Wolinsky JSA prospective open-label study of glatiramer acetate: over a decade of continuous use in MS patients. Mult Scler2006; 12: 309-320.
10.
Ebers GC, Heigenhauser L., Daumer M., Lederer C. and Noseworthy JHDisability as an outcome in MS clinical trials. Neurology2008; 71: 624-631.
11.
Maguire MJ, Hemming K., Hutton JL and Marson AGReporting and analysis of open-label extension studies of anti-epileptic drugs . Epilepsy Res2008; 81: 24-29.
12.
Coles A.Can the course of multiple sclerosis be modified?Pract Neurol2005; 5: 278-287.
13.
Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon-b-treated relapsing multiple sclerosis. Ann Neurol2007; 61: 300-306.
14.
Brown MG, Kirby S., Skedgel C., et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?Neurology2007; 69: 1498-1507.
15.
Trojano M., Pellegrini F., Paolicelli D., et al. Real-life impact of early interferon β therapy in relapsing multiple sclerosis. Ann Neurol2009; 66: 513-520.
16.
Rudick RA and Cutter G.Interferon-β for multiple sclerosis: long-term benefits?Ann Neurol2007; 61: 283-285.
17.
Heesen C., Gbadamosi J., Schoser BG, et al. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate - a case report. Eur J Neurol2001; 8: 199.
18.
Madray MM, Greene Jr JF and Butler DFGlatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol2008; 65: 1378-1379.
19.
Hashimoto S. , Ball NJ and Tremlett H.Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report. Mult Scler2009; 15: 521-522.
20.
Day RO and Williams KMOpen-label extension studies. Do they provide meaningful information on the safety of new drugs?Drug Saf2007; 30: 93-105.
21.
Taylor GJ and Wainwright P.Open label extension studies: research or marketing?Br Med J2005; 331: 572-574.
22.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. Neurology1995; 45: 1268-1276.
